Login to Your Account

Pharma: Other News To Note

Monday, December 10, 2012
• Alfa Wassermann SpA, of Bologna, Italy, and Norgine BV, of Amsterdam, the Netherlands, received European marketing authorization for Xifaxan 550-mg (rifaximin-alpha)/Refero/Targaxan/Tixteller for hepatic encephalopathy, a neuropsychiatric condition that can occur with cirrhosis of the liver.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription